VERACYTE, INC. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Veracyte reported Q3 2026 total revenue of $151.8M (+15% YoY) and testing revenue of $146.4M (+15%), driven by Decipher Prostate growth of 12% to $92.3M and Afirma growth of 19% to $51.5M. The company achieved GAAP net income of $31.5M (20.8% margin) and adjusted EBITDA of $41.2M (27.2% margin). The Board authorized a $100M share repurchase program; the company maintains $370.5M in cash and equivalents as of Sept 30, 2026. Full-year 2026 guidance narrowed to $590–593M revenue (14–15% growth), with adjusted EBITDA margin >26%.
Why this rating
Solid operational execution with 15% revenue growth and strong profitability; however, guidance was slightly reduced and Decipher Prostate missed expectations. $100M buyback (~5.8% of market cap) is modest and funds are available. Growth rate and margins are healthy but not transformational for a $1.7B company.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.